Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680164552c646-trace').style.display = (document.getElementById('cakeErr680164552c646-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680164552c646-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680164552c646-code').style.display = (document.getElementById('cakeErr680164552c646-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680164552c646-context').style.display = (document.getElementById('cakeErr680164552c646-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680164552c646-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680164552c646-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 15022,
		&#039;title&#039; =&gt; &#039;Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;
&lt;br /&gt;
Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;
&lt;br /&gt;
In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;
&lt;br /&gt;
Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;
The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;
&lt;br /&gt;
Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;
&lt;br /&gt;
Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;
&lt;br /&gt;
Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;
&lt;br /&gt;
If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;
&lt;br /&gt;
This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 15 May, 2012, http://economictimes.indiatimes.com/news/international-business/protests-in-us-over-high-pricing-of-novartis-anti-cancer-drug-glivec/articleshow/13141449.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15146,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 15022,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health,patents,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;&lt;br /&gt;Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;&lt;br /&gt;In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;&lt;br /&gt;Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;&lt;br /&gt;Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;&lt;br /&gt;Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;&lt;br /&gt;Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;&lt;br /&gt;If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;&lt;br /&gt;&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;&lt;br /&gt;This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 15022,
	&#039;title&#039; =&gt; &#039;Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;
&lt;br /&gt;
Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;
&lt;br /&gt;
In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;
&lt;br /&gt;
Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;
The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;
&lt;br /&gt;
Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;
&lt;br /&gt;
Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;
&lt;br /&gt;
Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;
&lt;br /&gt;
If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;
&lt;br /&gt;
This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 15 May, 2012, http://economictimes.indiatimes.com/news/international-business/protests-in-us-over-high-pricing-of-novartis-anti-cancer-drug-glivec/articleshow/13141449.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15146,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 15022
$metaTitle = &#039;LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;
$metaKeywords = &#039;Health,patents,medicines&#039;
$metaDesc = &#039;

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for...&#039;
$disp = &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;&lt;br /&gt;Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;&lt;br /&gt;In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;&lt;br /&gt;Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;&lt;br /&gt;Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;&lt;br /&gt;Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;&lt;br /&gt;Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;&lt;br /&gt;If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;&lt;br /&gt;&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;&lt;br /&gt;This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&#039; anti-cancer drug Glivec-Divya Rajagopal | Im4change.org</title>
    <meta name="description" content="

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Protests in US over high pricing of Novartis&#039; anti-cancer drug Glivec-Divya Rajagopal</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <br /><div align="justify">Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs.<br /><br />Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.<br /><br />In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month's dosage is $7,367, or roughly 3 lakh, in the US.<br /><br />Novartis' patent for the drug means that no generic exports can take place till 2015. &quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&quot; says the petition against Novartis. &quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&quot; it added.<br />The reason why this is important in India lies in a couple of ongoing cases in the country's courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.<br /><br />Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.<br /><br />Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.<br /><br />Whenever a patient needs a drug, it will be available, they have said. &quot;This is about safeguarding incentives for better medicines so that patients' needs would be met in future,&quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.<br /><br />If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.<br /><br />&quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.<br /><br />This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680164552c646-trace').style.display = (document.getElementById('cakeErr680164552c646-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680164552c646-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680164552c646-code').style.display = (document.getElementById('cakeErr680164552c646-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680164552c646-context').style.display = (document.getElementById('cakeErr680164552c646-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680164552c646-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680164552c646-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 15022,
		&#039;title&#039; =&gt; &#039;Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;
&lt;br /&gt;
Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;
&lt;br /&gt;
In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;
&lt;br /&gt;
Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;
The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;
&lt;br /&gt;
Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;
&lt;br /&gt;
Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;
&lt;br /&gt;
Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;
&lt;br /&gt;
If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;
&lt;br /&gt;
This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 15 May, 2012, http://economictimes.indiatimes.com/news/international-business/protests-in-us-over-high-pricing-of-novartis-anti-cancer-drug-glivec/articleshow/13141449.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15146,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 15022,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health,patents,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;&lt;br /&gt;Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;&lt;br /&gt;In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;&lt;br /&gt;Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;&lt;br /&gt;Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;&lt;br /&gt;Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;&lt;br /&gt;Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;&lt;br /&gt;If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;&lt;br /&gt;&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;&lt;br /&gt;This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 15022,
	&#039;title&#039; =&gt; &#039;Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;
&lt;br /&gt;
Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;
&lt;br /&gt;
In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;
&lt;br /&gt;
Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;
The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;
&lt;br /&gt;
Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;
&lt;br /&gt;
Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;
&lt;br /&gt;
Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;
&lt;br /&gt;
If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;
&lt;br /&gt;
This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 15 May, 2012, http://economictimes.indiatimes.com/news/international-business/protests-in-us-over-high-pricing-of-novartis-anti-cancer-drug-glivec/articleshow/13141449.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15146,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 15022
$metaTitle = &#039;LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;
$metaKeywords = &#039;Health,patents,medicines&#039;
$metaDesc = &#039;

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for...&#039;
$disp = &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;&lt;br /&gt;Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;&lt;br /&gt;In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;&lt;br /&gt;Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;&lt;br /&gt;Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;&lt;br /&gt;Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;&lt;br /&gt;Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;&lt;br /&gt;If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;&lt;br /&gt;&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;&lt;br /&gt;This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&#039; anti-cancer drug Glivec-Divya Rajagopal | Im4change.org</title>
    <meta name="description" content="

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Protests in US over high pricing of Novartis&#039; anti-cancer drug Glivec-Divya Rajagopal</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <br /><div align="justify">Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs.<br /><br />Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.<br /><br />In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month's dosage is $7,367, or roughly 3 lakh, in the US.<br /><br />Novartis' patent for the drug means that no generic exports can take place till 2015. &quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&quot; says the petition against Novartis. &quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&quot; it added.<br />The reason why this is important in India lies in a couple of ongoing cases in the country's courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.<br /><br />Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.<br /><br />Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.<br /><br />Whenever a patient needs a drug, it will be available, they have said. &quot;This is about safeguarding incentives for better medicines so that patients' needs would be met in future,&quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.<br /><br />If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.<br /><br />&quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.<br /><br />This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680164552c646-trace').style.display = (document.getElementById('cakeErr680164552c646-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680164552c646-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680164552c646-code').style.display = (document.getElementById('cakeErr680164552c646-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680164552c646-context').style.display = (document.getElementById('cakeErr680164552c646-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680164552c646-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680164552c646-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 15022,
		&#039;title&#039; =&gt; &#039;Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;
&lt;br /&gt;
Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;
&lt;br /&gt;
In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;
&lt;br /&gt;
Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;
The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;
&lt;br /&gt;
Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;
&lt;br /&gt;
Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;
&lt;br /&gt;
Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;
&lt;br /&gt;
If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;
&lt;br /&gt;
This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 15 May, 2012, http://economictimes.indiatimes.com/news/international-business/protests-in-us-over-high-pricing-of-novartis-anti-cancer-drug-glivec/articleshow/13141449.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15146,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 15022,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health,patents,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;&lt;br /&gt;Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;&lt;br /&gt;In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;&lt;br /&gt;Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;&lt;br /&gt;Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;&lt;br /&gt;Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;&lt;br /&gt;Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;&lt;br /&gt;If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;&lt;br /&gt;&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;&lt;br /&gt;This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 15022,
	&#039;title&#039; =&gt; &#039;Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;
&lt;br /&gt;
Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;
&lt;br /&gt;
In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;
&lt;br /&gt;
Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;
The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;
&lt;br /&gt;
Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;
&lt;br /&gt;
Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;
&lt;br /&gt;
Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;
&lt;br /&gt;
If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;
&lt;br /&gt;
This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 15 May, 2012, http://economictimes.indiatimes.com/news/international-business/protests-in-us-over-high-pricing-of-novartis-anti-cancer-drug-glivec/articleshow/13141449.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15146,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 15022
$metaTitle = &#039;LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&amp;#039; anti-cancer drug Glivec-Divya Rajagopal&#039;
$metaKeywords = &#039;Health,patents,medicines&#039;
$metaDesc = &#039;

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for...&#039;
$disp = &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs&#039; claims of cheap access and affordability for patented drugs.&lt;br /&gt;&lt;br /&gt;Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.&lt;br /&gt;&lt;br /&gt;In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month&#039;s dosage is $7,367, or roughly 3 lakh, in the US.&lt;br /&gt;&lt;br /&gt;Novartis&#039; patent for the drug means that no generic exports can take place till 2015. &amp;quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&amp;quot; says the petition against Novartis. &amp;quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&amp;quot; it added.&lt;br /&gt;The reason why this is important in India lies in a couple of ongoing cases in the country&#039;s courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.&lt;br /&gt;&lt;br /&gt;Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.&lt;br /&gt;&lt;br /&gt;Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.&lt;br /&gt;&lt;br /&gt;Whenever a patient needs a drug, it will be available, they have said. &amp;quot;This is about safeguarding incentives for better medicines so that patients&#039; needs would be met in future,&amp;quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.&lt;br /&gt;&lt;br /&gt;If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.&lt;br /&gt;&lt;br /&gt;&amp;quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.&lt;br /&gt;&lt;br /&gt;This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&amp;quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&#039; anti-cancer drug Glivec-Divya Rajagopal | Im4change.org</title>
    <meta name="description" content="

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Protests in US over high pricing of Novartis&#039; anti-cancer drug Glivec-Divya Rajagopal</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <br /><div align="justify">Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs.<br /><br />Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.<br /><br />In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month's dosage is $7,367, or roughly 3 lakh, in the US.<br /><br />Novartis' patent for the drug means that no generic exports can take place till 2015. &quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&quot; says the petition against Novartis. &quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&quot; it added.<br />The reason why this is important in India lies in a couple of ongoing cases in the country's courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.<br /><br />Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.<br /><br />Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.<br /><br />Whenever a patient needs a drug, it will be available, they have said. &quot;This is about safeguarding incentives for better medicines so that patients' needs would be met in future,&quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.<br /><br />If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.<br /><br />&quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.<br /><br />This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 15022,
		'title' => 'Protests in US over high pricing of Novartis' anti-cancer drug Glivec-Divya Rajagopal',
		'subheading' => '',
		'description' => '<br />
<div align="justify">
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs.<br />
<br />
Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.<br />
<br />
In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month's dosage is $7,367, or roughly 3 lakh, in the US.<br />
<br />
Novartis' patent for the drug means that no generic exports can take place till 2015. &quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&quot; says the petition against Novartis. &quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&quot; it added.<br />
The reason why this is important in India lies in a couple of ongoing cases in the country's courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.<br />
<br />
Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.<br />
<br />
Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.<br />
<br />
Whenever a patient needs a drug, it will be available, they have said. &quot;This is about safeguarding incentives for better medicines so that patients' needs would be met in future,&quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.<br />
<br />
If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.<br />
<br />
&quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.<br />
<br />
This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.
</div>',
		'credit_writer' => 'The Economic Times, 15 May, 2012, http://economictimes.indiatimes.com/news/international-business/protests-in-us-over-high-pricing-of-novartis-anti-cancer-drug-glivec/articleshow/13141449.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 15146,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 15022,
	'metaTitle' => 'LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&#039; anti-cancer drug Glivec-Divya Rajagopal',
	'metaKeywords' => 'Health,patents,medicines',
	'metaDesc' => '

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for...',
	'disp' => '<br /><div align="justify">Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs.<br /><br />Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.<br /><br />In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month's dosage is $7,367, or roughly 3 lakh, in the US.<br /><br />Novartis' patent for the drug means that no generic exports can take place till 2015. &quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&quot; says the petition against Novartis. &quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&quot; it added.<br />The reason why this is important in India lies in a couple of ongoing cases in the country's courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.<br /><br />Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.<br /><br />Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.<br /><br />Whenever a patient needs a drug, it will be available, they have said. &quot;This is about safeguarding incentives for better medicines so that patients' needs would be met in future,&quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.<br /><br />If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.<br /><br />&quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.<br /><br />This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 15022,
	'title' => 'Protests in US over high pricing of Novartis&#039; anti-cancer drug Glivec-Divya Rajagopal',
	'subheading' => '',
	'description' => '<br />
<div align="justify">
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs.<br />
<br />
Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.<br />
<br />
In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month's dosage is $7,367, or roughly 3 lakh, in the US.<br />
<br />
Novartis' patent for the drug means that no generic exports can take place till 2015. &quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&quot; says the petition against Novartis. &quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&quot; it added.<br />
The reason why this is important in India lies in a couple of ongoing cases in the country's courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.<br />
<br />
Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.<br />
<br />
Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.<br />
<br />
Whenever a patient needs a drug, it will be available, they have said. &quot;This is about safeguarding incentives for better medicines so that patients' needs would be met in future,&quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.<br />
<br />
If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.<br />
<br />
&quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.<br />
<br />
This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.
</div>',
	'credit_writer' => 'The Economic Times, 15 May, 2012, http://economictimes.indiatimes.com/news/international-business/protests-in-us-over-high-pricing-of-novartis-anti-cancer-drug-glivec/articleshow/13141449.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'protests-in-us-over-high-pricing-of-novartis039-anti-cancer-drug-glivec-divya-rajagopal-15146',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 15146,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 15022
$metaTitle = 'LATEST NEWS UPDATES | Protests in US over high pricing of Novartis&#039; anti-cancer drug Glivec-Divya Rajagopal'
$metaKeywords = 'Health,patents,medicines'
$metaDesc = '

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for...'
$disp = '<br /><div align="justify">Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs.<br /><br />Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say.<br /><br />In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month's dosage is $7,367, or roughly 3 lakh, in the US.<br /><br />Novartis' patent for the drug means that no generic exports can take place till 2015. &quot;Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive,&quot; says the petition against Novartis. &quot;Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec,&quot; it added.<br />The reason why this is important in India lies in a couple of ongoing cases in the country's courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec.<br /><br />Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues.<br /><br />Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues.<br /><br />Whenever a patient needs a drug, it will be available, they have said. &quot;This is about safeguarding incentives for better medicines so that patients' needs would be met in future,&quot; Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET.<br /><br />If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs.<br /><br />&quot;This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable.<br /><br />This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on,&quot; says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Protests in US over high pricing of Novartis' anti-cancer drug Glivec-Divya Rajagopal

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments and public to provide protection in the form of patents, analysts and health activists say. In a recent petition to the US Congress and the USFDA, over 300 petitioners have demanded that the Obama administration force Novartis to cut the price of Glivec, which they say is too high and has risen six times since its launch in 2001. The current price of 30mg Glivec tablets for a month's dosage is $7,367, or roughly 3 lakh, in the US. Novartis' patent for the drug means that no generic exports can take place till 2015. "Novartis must have paid their research costs long back, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep themselves alive," says the petition against Novartis. "Our US representatives should work with FDA to put pressure on Novartis to reduce the cost of Glivec," it added. The reason why this is important in India lies in a couple of ongoing cases in the country's courts. Rebuffed by the Madras High Court and the Intellectual Property Appellate Board, Novartis has appealed to the apex court to grant a patent for a new, improved version of Glivec. Bayer is also appealing a recent decision of the Indian government to grant a compulsory license to sell the generic version of lung cancer drug Nexavar to Natco Pharma. While the Glivec case is not really based on the prices, the Bayer judgment is based on affordability and access issues. Novartis did not respond to an email query sent by ET. But in past media interactions and public statements, Novartis and other pharma companies have been saying that lack of affordability and access are not the real issues. Whenever a patient needs a drug, it will be available, they have said. "This is about safeguarding incentives for better medicines so that patients' needs would be met in future," Ranjit Shahani, MD, Novartis India, had said in a previous email interaction with ET. If the Obama administration, supports this petition, it could make it very difficult for governments in India and other developing countries around the world to ignore the voices clamouring for sparse protection to patented drugs and public promotion of cheap, generic drugs. "This petition shows what patients are going through across the world, and this is in spite of insurance and patient assistance programmes of pharma companies. It seems the argument that Novartis makes that this drug is easily accessible for those who need it is questionable. This is precisely the concern with the access programes that Big Pharma talks about - they come with strings attached, especially on drugs that they have monopolies on," says Kajal Bhardwaj, a New Delhi-based independent lawyer working on health and human rights.